CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript - Thomson StreetEvents

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript - Thomson StreetEvents
CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript
Published Oct 12, 2021
11 pages (6775 words) — Published Oct 12, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

  
Brief Excerpt:

...Thank you, Sarah. Ladies and gentlemen, a warm welcome to this conference call from us here at CureVac, and welcome Rino Rappuoli, who we are happy to have participated in our call today from GSK Vaccine's headquarters in Belgium. The global fight against SARS-CoV-2 continues. However, the situation has changed considerably. Since the fight against COVID-19 began, licensed efficacious first-generation vaccines have become available, which have successfully helped to manage the initial peak demand to rapidly prime vaccinate unprecedentedly large populations. While the pandemic is still ongoing, the benefits of these vaccination efforts are easy to observe. Globally, COVID-19 cases and deaths reported [weakened] as the WHO continued to decline after reaching an interim peak earlier this year as a result of the rapid spread of the Delta variant. Today, a wind down -- a downward trend in weekly COVID-19 cases can be observed continuously,...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
CureVac NV
Ticker
CVAC.OQ
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

CureVac NV Q4 2021 Earnings Call Summary – 2022-04-28 – US$ 54.00 – Edited Brief of CVAC.OQ earnings conference call or presentation 28-Apr-22 1:00pm GMT

CureVac NV Q4 2021 Earnings Call Transcript – 2022-04-28 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 28-Apr-22 1:00pm GMT

CureVac NV Q3 2021 Earnings Call Summary – 2021-11-19 – US$ 54.00 – Edited Brief of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV Q3 2021 Earnings Call Transcript – 2021-11-19 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary – 2021-10-12 – US$ 54.00 – Edited Brief of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript – 2021-07-01 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 1-Jul-21 12:00pm GMT

CureVac NV Updates On Clinical Trial - Corporate Call Transcript – 2021-06-17 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 17-Jun-21 12:00pm GMT

CureVac NV Q4 2020 Earnings Call Transcript – 2021-04-15 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 15-Apr-21 2:00pm GMT

CureVac N.V. - Special Call Transcript – 2021-02-05 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 5-Feb-21 3:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript" Oct 12, 2021. Alacra Store. May 02, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/CureVac-NV-To-Discuss-the-Shift-Focus-of-COVID-19-Vaccine-Development-to-Second-Generation-mRNA-Technology-Call-T15005592>
  
APA:
Thomson StreetEvents. (2021). CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript Oct 12, 2021. New York, NY: Alacra Store. Retrieved May 02, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/CureVac-NV-To-Discuss-the-Shift-Focus-of-COVID-19-Vaccine-Development-to-Second-Generation-mRNA-Technology-Call-T15005592>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.